Loading...
Market
Which company will be the next major competitor in MS treatments by 2025?
2
Resolution / Starting Odds
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Industry news and press releases from pharmaceutical companies
Story
TG Therapeutics ($TGTX) Reports Positive ENHANCE Phase 3b Data on Briumvi for Multiple Sclerosis
Oct 14, 2024, 11:37 AM
TG Therapeutics ($TGTX) has released new data from its ENHANCE Phase 3b study, showing that rapid 30-minute infusions of Briumvi (ublituximab-xiiy) are well tolerated in patients with relapsing forms of multiple sclerosis. This comes amid comparisons with SubQ Ocrevus, which requires a 10-minute delivery of 23ml of fluid under the skin, potentially causing discomfort and bruising. The total treatment time for SubQ Ocrevus is approximately 1.5 hours, compared to 4.5 hours for IV Ocrevus. KOLS do not favor SubQ Ocrevus, and the Briumvi switching trial is showing promising results.
View original story
Similar markets
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
AbbVie • 25%
Bristol Myers Squibb • 25%
Another major pharmaceutical company • 25%
No new approvals • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
CRISPR Therapeutics • 25%
Intellia Therapeutics • 25%
Beam Therapeutics • 25%
Other • 25%
Eli Lilly • 25%
Eisai and Biogen • 25%
Other companies • 25%
No dominant company • 25%
Moderna • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
Novo Nordisk • 25%
Sanofi • 25%
Eli Lilly • 25%
Other • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%